Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

Matta WH; Shaw RW; Hesp R; Katz D

doi:10.1136/bmj.294.6586.1523

Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

Matta WH, Shaw RW, Hesp R, Katz D

British medical journal (Clinical research ed.) · 1987 · doi:10.1136/bmj.294.6586.1523 · PMID:3111619 · PMC1246674

OA: closed

📄 Open PDF View on PubMed View at publisher

⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

This paper investigates the effects of luteinising hormone releasing hormone agonist analogues on bone density in premenopausal women experiencing induced hypogonadism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992

Cited by (1)

Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992

Source provenance

europepmc: last seen: 2026-09-20T09:27:46.357103+00:00
unpaywall: last seen: 2026-09-22T06:12:16.469521+00:00